Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy

Nanoscale ◽  
2017 ◽  
Vol 9 (37) ◽  
pp. 13879-13904 ◽  
Author(s):  
Xu Wu ◽  
Shengpeng Wang ◽  
Mingxing Li ◽  
Anqi Wang ◽  
Yangyang Zhou ◽  
...  

TRAIL-based nanotherapies improve stability, prolong half-life in plasma, specifically deliver to a target site, and overcome resistance of TRAIL.

2019 ◽  
Vol 44 (1) ◽  
pp. 89-101
Author(s):  
H Rahman ◽  
T Akter ◽  
HK Mishu ◽  
RU Miah ◽  
MS Alam

The assessment of residual behavior of imidacloprid (Admire 20SL) in the soil of country bean agroecosystem and its risk assessment for consumption was studied. QuEChERS method was used for the extraction and clean-up of samples and the residues of imidacloprid was estimated using Gas Chromatography. The dissipation studies in the soil system were carried out by application of imidacloprid at five different dosages i.e. 100, 200, 300, 400, and 500 g a.i. ha-1. Average initial deposits of imidacloprid were found to be 0.99, 1.33, 1.62, 1.83 and 2.20 mg.kg-1. The residues reached below determination limit (BDL) of 0.01 mg kg-1 in 9 days for recommended dose and 12 days for remaining higher dosages. Half-life (T1/2)) of imidacloprid in the soil was observed to be 1.88, 1.74, 1.73, 1.56 and 1.52 days for 100, 200, 300, 400, and 500 g a.i. ha-1, respectively. The chemodynamics study of imidacloprid spray indicated that only 27.20 -28.40% sprays were deposited to the target site (plant canopy) and 71.60-72.80% were lost to non-target site such as soil and air. The drift of imidacloprid to soil (39.47-40.20%) was higher than the air (32.13-32.60%). Based on degradation pattern and maximum, the recommended preharvest interval (PHI) might be eight 9 days and a waiting period of two days might be suggested for reapplication of the imidacloprid in country bean agroecosystem. Bangladesh J. Agril. Res. 44(1): 89-101, March 2019


2021 ◽  
Vol 11 ◽  
Author(s):  
Xiao-Xin Sun ◽  
Yanping Li ◽  
Rosalie C. Sears ◽  
Mu-Shui Dai

Deregulated MYC overexpression and activation contributes to tumor growth and progression. Given the short half-life and unstable nature of the MYC protein, it is not surprising that the oncoprotein is highly regulated via diverse posttranslational mechanisms. Among them, ubiquitination dynamically controls the levels and activity of MYC during normal cell growth and homeostasis, whereas the disturbance of the ubiquitination/deubiquitination balance enables unwanted MYC stabilization and activation. In addition, MYC is also regulated by SUMOylation which crosstalks with the ubiquitination pathway and controls MYC protein stability and activity. In this mini-review, we will summarize current updates regarding MYC ubiquitination and provide perspectives about these MYC regulators as potential therapeutic targets in cancer.


2018 ◽  
pp. 118-124
Author(s):  
Sulaiman Sulaiman ◽  
Sri Aguswarini ◽  
Karyadi Karyadi ◽  
Chairuman Chairuman ◽  
Gatot Setiawan ◽  
...  

Cancer is one of the causes of death in Indonesia and even the world. Nuclear medicine techniques with radiopharmaceuticals and SPECT are one of the ways to treat cancer, but their use in Indonesia is not yet popular. Radiopharmaceuticals marked with radionuclide emitting beta (β) radiation are proven to be used for cancer therapy, one that has been developed in PTRR-BATAN is 90Y-EDTMP. Yttrium-90 is used in nuclear medicine by utilizing β radiation (E max 2.28 MeV). The β energy which is produced from the decay process of 90Y radionuclides to 90Zr can kill cancer cells. This study aimed to provide information about the substances biological effects so that preventive measures can be taken to protect humans. This study conducted evaluation of the 90Y-marked radiopharmaceutical (90Y produced from a 90Sr / 90Y generator which is 90Y-EDTMP) encompasses clearance test, pyrogen test, and dose safety test in experimental animals. The clearance test utilized mice, the pyrogen test utilized rabbits, and the dose safety test utilized mice. The results of the clearance test showed that 90Y-EDTMP compound which was excreted in 192 hour was 49.70% through urine and 14.59% through feces. The total excretion of 90Y-EDTMP within 192 hours was 64.57%. Based on the results of clearance tests with calculations, 90Y of 90Sr / 90Y generators in 90Y-EDTMP dosage form had 84.2 hours of half-life, 36.5 hours of an effective half-life and 52.7 hours of a residence time. Pyrogen test results showed pyrogen-free. The 90Y-EDTMP dose safety test showed that the dose is safe and not deadly. The development of 90Y-EDTMP is expected to be improved to produce radiopharmaceuticals for cancer therapy in order to make a real contribution in public health services.


RSC Advances ◽  
2016 ◽  
Vol 6 (78) ◽  
pp. 74254-74268 ◽  
Author(s):  
Mahalingam Rajamanickam Vijayakumar ◽  
Ramoji Kosuru ◽  
Sanjay Kumar Singh ◽  
Chandra Bhushan Prasad ◽  
Gopeshwar Narayan ◽  
...  

The systemic circulation time and biological half-life of trans-Resveratrol (RSV) is enhanced using poly(d,l-lactide-co-glycolide)–d-α-tocopheryl polyethylene glycol 1000 succinate blend nanoparticles (RSV-PLGA-BNPs).


2021 ◽  
Vol 12 ◽  
Author(s):  
Yihui Zhou ◽  
Xiaomeng Gao ◽  
Meng Yuan ◽  
Bo Yang ◽  
Qiaojun He ◽  
...  

MYC, as a well-known oncogene, plays essential roles in promoting tumor occurrence, development, invasion and metastasis in many kinds of solid tumors and hematologic neoplasms. In tumors, the low expression and the short half-life of Myc are reversed, cause tumorigenesis. And proteins that directly interact with different Myc domains have exerted a significant impact in the process of Myc-driven carcinogenesis. Apart from affecting the transcription of Myc target genes, Myc interaction proteins also regulate the stability of Myc through acetylation, methylation, phosphorylation and other post-translational modifications, as well as competitive combination with Myc. In this review, we summarize a series of Myc interacting proteins and recent advances in the related inhibitors, hoping that can provide new opportunities for Myc-driven cancer treatment.


2021 ◽  
Author(s):  
Jintong Liu ◽  
Jing Huang ◽  
Lei Zhang ◽  
Jianping Lei

We review the general principle of the design and functional modulation of nanoscaled MOF heterostructures, and biomedical applications in enhanced therapy.


1991 ◽  
Vol 36 (5) ◽  
pp. 455-455
Author(s):  
Michael J. Mahoney
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document